Valeo Pharma (VPH) Stock Price, News & Analysis

Company Overview

Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson's disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic. In addition, the company provides Ametop Gel 4% for skin anesthesia prior to injection or cannulation; Sabizabulin, an antiviral and anti-inflammatory agent for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and death; Simbrinza, ophthalmic drops to treat openangle glaucoma or ocular hypertension; Xiidra, a prescription based eye-drop to treat dry eye disease; and Allerject, a portable voice-activated epinephrine injector for emergency treatment of serious allergic reactions. Its primary therapeutic areas include respiratory/allergy, ophthalmology, neurology, oncology, and specialty products. The company was incorporated in 2003 and is based in Kirkland, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 51,000 shs
• Average Volume: 59,093 shs
• Market Capitalization: C$4.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: TSE:VPH
• CIK: N/A
• Web: www.valeopharma.com
• Phone: 514-694-0150
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C($0.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -C$32.12 million
• Net Margins: -60.18%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -26.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.27
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: C$53.38 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: C($0.64) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 98,660,000
• Free Float: N/A
• Market Cap: C$4.44 million
• Optionable: Not Optionable
• Beta: 2.32